What does GRI Bio do?

GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.
GRI Bio company media

Company Snapshot

key

Ownership

Public
people

Employees

4
pie chart

Sector

Health Care
location pin

Head Office

La Jolla, United States
founded flag

Year Founded

2009

What does GRI Bio specialise in?

/Real Estate Investments /Global Diversification /Asset Management /Equity Portfolio /Fund Management /Investment Research

What are the products and/or services of GRI Bio?

Overview of GRI Bio offerings
Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.

Who is in the executive team of GRI Bio?

GRI Bio leadership team
  • Photo of Dr. W. Marc Hertz Ph.D.
    Dr. W. Marc Hertz Ph.D.
    Co-Founder, CEO, President & Director
  • Photo of Dr. Vipin Kumar Chaturvedi Ph.D.
    Dr. Vipin Kumar Chaturvedi Ph.D.
    Co-Founder & Chief Scientific Officer
  • Photo of Ms. Leanne M. Kelly
    Ms. Leanne M. Kelly
    CFO & Corporate Secretary
  • Photo of Dr. Albert Agro Ph.d.
    Dr. Albert Agro Ph.d.
    Co-Founder & Chief Medical Officer